Axsome therapeutics COO Mark Jacobson sells $4.23 million in shares

Axsome Therapeutics COO Mark Jacobson sold 40,673 shares for $4.23 million on May 27-28 under a pre-approved 10b5-1 plan, reducing his direct ownership to 5,783 shares, despite analysts maintaining a strong buy consensus with price targets ranging from $146 to $210. The sales occurred after Jacobson exercised options to acquire the same number of shares at a significantly lower price. This development comes as Axsome reported a narrower-than-expected Q1 loss, secured a $570 million credit facility from Blackstone, and settled a patent dispute, while analysts adjust price targets reflecting both optimism about prescription growth and concerns about operating expenses.

Analysis

Axsome Therapeutics' Chief Operating Officer, Mark Jacobson, recently sold 40,673 shares for approximately $4.23 million between May 27 and 28, at prices ranging from $103.45 to $104.66 per share. This transaction, part of a pre-approved 10b5-1 plan, followed Jacobson's exercise of stock options to acquire these shares at $6.47 each, subsequently reducing his direct ownership to 5,783 shares. Despite this insider disposition, Axsome Therapeutics, valued at $5.07 billion, demonstrates robust financial health with reported revenue growth of 72% and sustained gross profit margins exceeding 91%. The company's first-quarter 2025 earnings reported a loss of $1.22 per share, outperforming analyst expectations of a $1.30 loss, while revenue reached $121.46 million, marking a 62% year-over-year increase though marginally below the $121.58 million forecast. Key strategic moves include securing a $570 million credit facility from Blackstone for enhanced financial flexibility and debt retirement, and a patent dispute settlement for SUNOSI allowing a generic launch in 2040. Analyst sentiment remains strong with a buy consensus and price targets ranging from $146 to $210. For instance, BofA Securities increased its price target to $176, citing strong Auvelity-MDD prescription growth, while H.C. Wainwright maintained a Buy rating but lowered its target to $180 due to higher operating expense projections. The company's cash reserves of $300.9 million are anticipated to fund operations until cash flow positivity, with future growth potentially driven by the upcoming launch of SYMBRAVO for migraines and an InvestingPro assessment suggesting the stock currently trades below its fair value.

Key Decisions for Investors

• Investors should consider the COO's stock sale within the context of a pre-arranged 10b5-1 plan and the substantially profitable exercise of stock options, which may indicate strategic financial planning rather than a lack of confidence in Axsome's prospects.
• Focus on the company's strong underlying fundamentals, including significant revenue growth (72% overall, 62% YoY in Q1), high gross profit margins (over 91%), and a robust analyst buy consensus with price targets indicating substantial upside, despite current unprofitability.
• Monitor key upcoming catalysts such as the launch of SYMBRAVO, continued prescription growth for Auvelity-MDD, and the company's management of operating expenses, while also noting the potential undervaluation suggested by InvestingPro and the enhanced financial stability from the new credit facility.